### P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Resveratrol CAS Number: 501-36-0 Date Report Requested: 08/26/2019 Time Report Requested: 17:01:32 First Dose M/F: 10/16/06 / 10/16/06 Lab: BAT

NTP Study Number:	C20323
Lock Date:	12/15/2006
Cage Range:	ALL
Date Range:	ALL
Reasons For Removal:	ALL
Removal Date Range:	ALL
Treatment Groups:	Include ALL
Study Gender:	Both
TDMSE Version:	3.0.2.3_002
PWG Approval Date:	NONE

#### P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Resveratrol **CAS Number:** 501-36-0

Date Report Requested: 08/26/2019 Time Report Requested: 17:01:32 First Dose M/F: 10/16/06 / 10/16/06 Lab: BAT

DOSE	156 mg/kg	1250 mg/kg
Liver		
Hepatodiaphragmatic Nodul	e	
LESION RATES		
OVERALL (a)	2/2 (100%)	1/1 (100%)
POLY-3 RATE (b)	2/2.00	1/1.00
POLY-3 PERCENT (g)	100%	100%
TERMINAL (d)	2/2 (100%)	1/1 (100%)
FIRST INCIDENCE	16 (T)	16 (T)
STATISTICAL TESTS		
POLY 3		(e)
POLY 1.5		(e)
POLY 6		(e)
COCH-ARM / FISHERS		(e)
MAX-ISO-POLY-3		(e)

#### P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Resveratrol **CAS Number:** 501-36-0

Date Report Requested: 08/26/2019 Time Report Requested: 17:01:32 First Dose M/F: 10/16/06 / 10/16/06 Lab: BAT

			Males	
DOSE	156 mg/kg	1250 mg/kg		
Liver				
Inflammation Chronic				
LESION RATES				
OVERALL (a)	0/2 (0%)	1/1 (100%)		
POLY-3 RATE (b)	0/2.00	1/1.00		
POLY-3 PERCENT (g)	0%	100%		
TERMINAL (d)	0/2 (0%)	1/1 (100%)		
FIRST INCIDENCE		16 (T)		
STATISTICAL TESTS				
POLY 3		(n)		
POLY 1.5		(n)		
POLY 6		(n)		
COCH-ARM / FISHERS		(n)		
MAX-ISO-POLY-3		(n)		

#### P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Resveratrol **CAS Number:** 501-36-0

Date Report Requested: 08/26/2019 Time Report Requested: 17:01:32 First Dose M/F: 10/16/06 / 10/16/06 Lab: BAT

			Females
DOSE	78 mg/kg	1250 mg/kg	
Liver	la.		
Hepatodiaphragmatic Nodu	le		
LESION RATES			
OVERALL (a)	0/0 (0%)	2/2 (100%)	
POLY-3 RATE (b)	0/0.00	2/2.00	
POLY-3 PERCENT (g)	0%	100%	
TERMINAL (d)	0/0 (0%)	2/2 (100%)	
FIRST INCIDENCE		16 (T)	
STATISTICAL TESTS			
POLY 3		(e)	
POLY 1.5		(e)	
POLY 6		(e)	
COCH-ARM / FISHERS		(e)	
MAX-ISO-POLY-3		(e)	

#### P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Resveratrol **CAS Number:** 501-36-0

Date Report Requested: 08/26/2019 Time Report Requested: 17:01:32 First Dose M/F: 10/16/06 / 10/16/06 Lab: BAT

			Females
DOSE	78 mg/kg	1250 mg/kg	
Liver Inflammation Chronic			
LESION RATES			
OVERALL (a)	0/0 (0%)	2/2 (100%)	
POLY-3 RATE (b)	0/0.00	2/2.00	
POLY-3 PERCENT (g)	0%	100%	
TERMINAL (d)	0/0 (0%)	2/2 (100%)	
FIRST INCIDENCE		16 (T)	
STATISTICAL TESTS			
POLY 3		(e)	
POLY 1.5		(e)	
POLY 6		(e)	
COCH-ARM / FISHERS		(e)	
MAX-ISO-POLY-3		(e)	

### P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Resveratrol CAS Number: 501-36-0 Date Report Requested: 08/26/2019 Time Report Requested: 17:01:32 First Dose M/F: 10/16/06 / 10/16/06 Lab: BAT

### LEGEND

(a)	Number of tumor-bearing animals/number of animals examined at site.
(b)	Number of tumor-bearing animals/Poly-3 number
(d)	Observed incidence at terminal kill.
(e)	Value of statistic cannot be computed.
(f)	Beneath the control incidence are the P-values associated with the trend test. Beneath the dosed group incidence are the P-values corresponding to pairwise comparisons between the controls and that dosed group.
(g)	Poly-3 adjusted lifetime tumor incidence.
(n)	No statistics are calculated if all dose groups have fewer than two tumors.
(I)	Interim sacrifice
(T)	Terminal sacrifice
#	Tumor rates based on numbers of animals necropsied.
*	To the right of any statistical result, indicates significance at (P<=0.05).
**	To the right of any statistical result, indicates significance at (P<=0.01).
Ν	Indicates a negative trend for all tests
	The Cochran-Armitage and Fishers exact tests compare directly the overall incidence rates.
	*** END OF REPORT ***